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Abstract
Objective: To examine the association between refugee status and elevated blood lead levels 
(EBLLs) among children living in two U.S. cities and to assess the effect of the Centers for 
Disease Control and Prevention recommendations for BLL testing of newly emigrated refugee 
children for EBLLs.
Design and Sample: A longitudinal study was conducted of 1,007 refugee children and 953 
nonrefugee children living, when blood testing occurred, in the same buildings in Manchester, 
New Hampshire and Providence, Rhode Island.
Measures: Surveillance and blood lead data were collected from both sites, including 
demographic information, BLLs, sample type, refugee status, and age of housing.
Results: Refugee children living in Manchester were statistically significantly more likely to 
have an EBLL compared with nonrefugee children even after controlling for potential 
confounders. We did not find this association in Providence. Compared with before enactment, the 
mean time of refugee children to fall below 10 μg/dL was significantly shorter after the 
recommendations to test newly emigrated children were enacted.
Conclusions: Refugee children living in Manchester were significantly more likely to have an 
EBLL compared with nonrefugee children. And among refugee children, we found a statistically 
significant difference in the mean days to BLL decline <10 μg/dL before and after 
recommendations to test newly emigrated children.
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Background
Lead poisoning is a preventable environmental condition. Yet the Centers for Disease 
Control and Prevention (CDC) estimates that approximately 250,000 children aged 1–5 
years are affected (CDC, 2011). The adverse effects of lead in children have been well 
documented. Exposure to lead can harm a child’s renal, nervous, and hematopoietic systems 
(Agency for Toxic Substances and Disease Registry [ATSDR], 1988; Lidsky & Schneider, 
2003) and no safe blood lead level (BLL) in children has been identified. The most highly 
concentrated source of lead for most children in the United States is lead paint in homes 
built before 1978 (ATSDR, 1988).
In 2004, CDC issued recommendations for testing the BLL of newly arrived refugee 
children aged 6 months–16 years (CDC, 2004). The recommendations followed reports in 
2001 that stated refugee children who resettled in the United States were at high risk for lead 
poisoning (Geltman, Brown, & Cochran, 2001). The recommendations also stemmed from 
the death of a newly emigrated 2-year-old Sudanese girl from lead poisoning in early 2000 
(CDC, 2001) and the increased prevalence of elevated blood lead levels (EBLLs) among 
newly resettled refugee children compared with that of U.S. children (CDC, 2004). As a 
result, CDC worked with the Office of Global Health Affairs; Office of Refugee 
Resettlement, and the U.S. Department of State, Bureau of Population, Refugees and 
Migration to develop a set of guidelines for testing newly emigrated refugee children for 
lead poisoning. The CDC’s recommendations for testing newly emigrated refugee children 
for lead are:
1. All refugee children between 6 months and 16 years of age have a blood lead test 
within 90 days of arrival to the United States.
2. A repeat blood lead test of all refugee children 6 months–6 years of age 3–6 
months after refugee children are placed in permanent residences, older children 
if warranted, regardless of initial blood lead test results.
3. Timely and appropriate follow-up of children with EBLLs.
Since 2004, little research has been conducted to evaluate CDC’s guidelines on blood lead 
testing of newly arrived refugee children.
Our study’s objectives were to determine whether the CDC recommendations to test and 
educate newly emigrated refugee children and their families were instrumental in decreasing 
the prevalence of EBLLs among this population. We compiled data from the New 
Hampshire Lead Poisoning Prevention Program (NH CLPPP) and the Rhode Island Lead 
Poisoning Prevention Program (RI CLPPP) for both newly arrived refugee children and 
nonrefugee children living in the same buildings.
Research Hypotheses
Our goals were to determine whether:
1. Refugee children were more likely to have an elevated BLL,
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2. Any differences occurred in the amount of time refugee and nonrefugee children 
reached BLLs <10 μg/dL, and
3. Recommendations to test newly emigrated children significantly affected the 
time for BLLs to drop below 10 μg/dL.
Methods
Design and sample
We conducted a longitudinal study to examine the association between refugee status and 
BLL among children. To assess this association, we examined BLLs of refugee and 
nonrefugee children living in the same building at the time of the blood lead test. We 
considered cities for inclusion in this study if they (1) could identify refugee children in the 
childhood lead poisoning prevention program (CLPPP) surveillance database between 2001 
and June 2010, and (2) had protocols for blood lead testing refugee children within 90 days 
of relocation to the United States and again 60–90 days after their initial blood lead test. 
Both Manchester, which implemented the recommendation in 2001, and Providence, which 
implemented the recommendation in 2004, met these criteria. Manchester was home to 639 
eligible children; Providence to 368.
We defined a child as anyone <16 years of age in the database with a valid blood lead test 
and an address of residence in one of the two cities. Nonrefugee children were included in 
the study if they lived in the same building as a refugee child during the time of the 
nonrefugee child’s blood lead test (n = 253 in Manchester, NH and n = 700 for Providence, 
RI) and if they had a blood lead test between January 1995 and June 2010. We collected 
from the NH and RI CLPPP blood lead surveillance systems, both of which collect 
laboratory-based reports of blood lead results from across their respective states.
Measures
We obtained demographic information including gender, race, age in months at the time of 
the blood lead test, sample type of the blood lead test (venous or capillary), and age of 
housing. To determine age of housing, we examined tax assessor data from Providence and 
Manchester for a particular address. We then linked housing information to blood lead data 
to match each child to a particular address. We defined a confirmed EBLL as a child with 
one venous BLL ≥10 μg/dL or two capillary blood lead tests within 12 weeks, both with a 
result ≥10 μg/dL. In analyses with more than one blood lead test per child, we used the 
highest venous confirmed EBLL or second capillary. We coded any unknown blood lead 
sample type as a capillary sample. The final sample consisted of 1,957 uniquely identified 
children.
IRB approval was exempted by CDC’s Human Subject Matter review because (1) CDC’s 
Healthy Homes and Lead Poisoning Prevention Branch has a cooperative agreement with the 
two states that collect data, strip all identifiable information, and send the data to CDC on a 
quarterly basis (and, therefore, all human subject data had been stripped of identifiable 
information prior to CDC collecting the data for the study—Child and Address IDs were 
used instead of names and physical addresses) and (2) CDC collects these data from state 
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and local health departments, which thus falls under a blanket approval for CDC’s 
Childhood Blood Lead Surveillance (CBLS) system.
Analytic strategy
We calculated odds ratios (OR) and 95% confidence intervals (95% CI) using generalized 
estimating equation (GEE); nonrefugee children are not independent from the refugee 
population in that both groups of children shared a common characteristic—the buildings 
they lived in (Liang & Zeger, 1986). In addition, a particular child could have been included 
in the analysis in multiple years if he or she had multiple blood lead tests irrespective of the 
BLL. Regarding the main effects model, we did not choose only one BLL to represent each 
child. Instead, we calculated the association between BLL and refugee status of the 
correlated data with GEE to include as many blood lead tests as possible (Liang & Zeger, 
1986). To control for the effect of confounding, demographic variables associated with risk 
for EBLLs were included in the model to determine whether the association between BLL 
and refugee status remained statistically significant. We also examined second order 
associations to determine effect modification between refugee status and a priori-selected 
demographic variables. We created a design variable for age with the categories under 2 
years of age, 2 years of age, 3–5 years of age, and 6+ years of age (referent category). The 
year of the blood lead test was as follows: January 1, 1995–December 31, 2002, January 1, 
2003–December 31, 2006, and January 1, 2007–June 2010 (referent). The age of the housing 
unit was an ordinal variable categorized as pre-1950, 1950–1978, and post-1978 (referent).
We developed Kaplan–Meier survival curves (KM) to determine differences in time-to-
decline in BLL before and after recommendations were established. Highest confirmed 
elevated BLL was treated as a categorical variable in increments of 10 μg/dL. Only children 
with at least two BLLs—one confirmatory elevated BLL and at least one other test following 
the elevated BLL—were included in the survival curve. Follow-up stopped at the time when 
the child’s BLL dropped below 10 μg/dL (Kalbfleisch & Prentice, 1980). Children who were 
followed but who never fell below 10 μg/dL during the study period or who were lost to 
follow-up were censored at the time of their last blood lead test. Since we found that 
children did not differ by City, we combined children from Manchester and Providence to 
give a stronger power for the analysis.
We used the two-tailed Student’s t-test to examine whether the mean days to BLL dropping 
below 10 μg/dL before and after recommendations differed between refugee and nonrefugee 
children. Stratified analyses determined whether these differences remained significant when 
controlling for initial EBLL.
The Cox Proportional Hazards model identified decline predictors. The predictor variables 
of interest included:
• City the child was residing in during the blood lead test.
• Age of the child at the time of the blood lead test.
• Year of the blood lead test.
• Gender.
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• Time of the year of the blood lead test (summer months vs. Other times of the 
year).
• Highest confirmed elevated BLL.
Age of housing and sample type were not included in the proportional hazards model. Most 
children lived in pre-1950 housing units (96%) and had venous sample types (86%). All 
analyses were done using SAS version 9.2 (2008; SAS Institute Inc., Cary, NC, USA).
Results
Demographic information
There were a total of 1,960 children included in the analysis. Of these, 1,007 were refugee 
children who had blood lead tests within 90 days of entry into the United States. Refugee 
children tended to be older, less likely to have a venous blood lead sample, and slightly less 
likely to have an EBLL in the summer when compared with nonrefugee children living in 
the same buildings (Table 1). Sixty-three percent of the refugee children lived in Manchester. 
At the time of their blood lead test, approximately 61% of the total refugee population had at 
least one venous blood lead test sample, and 22.5% (227) had confirmed elevated BLLs, and 
87.5% lived in a pre-1950 housing unit (Table 1). Of the 953 nonrefugee children living in 
the same buildings as refugee children at the time of the blood lead test, some 54% lived in 
Providence. Among these nonrefugee children, over 87% had at least one venous blood lead 
test sample at the time of their blood lead test, 23% had confirmed elevated BLLs, and 
almost 89% lived in a pre-1950 housing unit (Table 1).
Refugee and nonrefugee children results were similar regarding gender (52% vs. 49% males, 
respectively). For both Providence and Manchester, however, when compared with the 
nonrefugee children, a significantly higher proportion of refugee children were older, over 6 
years of age (p < .0001) and had venous blood lead test samples (p < .0001). In addition, 
refugee children in Providence were more likely than were nonrefugee children to live in 
pre-1950 housing units (97% vs. 92%, p = .0002). Nonrefugee children in Providence were 
more likely than were refugee children to be identified with elevated BLLs in warm weather 
months compared with other times of the year (p = .0002) (Table 1).
In Providence, a higher proportion of nonrefugee children had EBLLs as compared with 
refugee children, while in Manchester the reverse was the case—refugee children were twice 
as likely to have an EBLL as compared with nonrefugee children (Table 2).
Refugee status and elevated blood lead level
To determine whether the association between refugee status and EBLL remained 
statistically significant in Manchester even after controlling for potential confounders, we 
calculated the adjusted odds ratio. The evidence suggested that even after controlling 
demographic risk factors, refugee children living in Manchester continued to be twice as 
likely to have an EBLL compared with nonrefugee children, OR = 2.09, 95% CI = 1.18–3.69 
(Table 2). In Providence, however, the association remained insignificant, OR = 1.23, 95% 
CI = .87–1.75 (Table 2).
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Time to blood lead level decline below 10 μg/dL.
Figure 1 describes the KM curves for children stratified by refugee status before and after 
recommendations to test newly emigrated children. The location of the curves at each 
successive 250-day increment after entry signifies the percentage of each cohort still 
elevated. While the rates of decline before and after the recommendations were similar for 
refugee and nonrefugee children, the figure also shows statistically significant differences in 
the mean days-to-decline among refugee children (Table 4). While an overall decrease 
occurred in the mean days-to-decline for nonrefugee children before and after 
recommendations—792 days to 507 days—a near 50% decrease occurred in the number of 
days-to-decline among refugee children—889 days to 471 days—and this decrease was 
statistically significant, p = .0001 (Table 3).
Predictors of blood lead level decline.
Results from Cox Proportional Hazards Model suggest that the year of confirmed EBLL was 
significantly associated with time to when a child’s BLL dropped below <10 μg/dL (Table 
4). We found that the BLLs of children who were identified and confirmed with EBLL 
before the recommendations were established, between 1995 and 2002, took significantly 
longer to decline below 10 μg/dL compared with children who were identified and 
confirmed with EBLL after the recommendations were in place (2003–2010) (Table 4). This 
association remained regardless of refugee status For example, children who were identified 
and confirmed with EBLL before the recommendations were in place, between 1995 and 
2002, took twice as long to decline less than 10 μg/dL compared with children identified and 
confirmed soon after recommendations were in place (2003–2006) (hazard ratio [HR] = 
1.80, p = .021). The decline was six times faster among children identified and confirmed 
with EBLL between 2007 and 2010 compared with those identified and confirmed before 
recommendations were in place (HR = 5.86, p < .0001) (Table 4). In addition, compared 
with children older than 6 years of age, the BLL of children <2 years of age took 
significantly longer to decline (HR = .56, p = .030) (Table 4). Regarding the rate of decline 
based on initial blood lead levels, children whose initial BLL was 15–19 μg/dL declined 
significantly slower compared to children with an initial EBLL between 10 and 14 μg/dL 
(HR = .47 p = .001) (Table 4). Similar results were found for children with an initial EBLL 
greater than that of 20 μg/dL (Table 4).
Discussion
Refugee children in Manchester were more likely to have an elevated BLL compared with 
nonrefugee children. This was not true in Providence (Table 2) where the proportion of 
nonrefugee children with a confirmed EBLL was higher than refugee children, though it was 
not statistically significant. One reason for this outcome could have been risk factors among 
nonrefugee children in Providence that would have made them more likely to have an EBLL, 
for example, race/ethnicity, exposure to dust lead, and condition of the house during the time 
of the blood lead test were not collected in this study. Another possible reason for more 
EBLLs in Manchester refugee children was the high number of capillary tests compared 
with nonrefugee children. Capillary tests have a much higher risk of contamination. Follow-
up testing is required if a child has an elevated capillary blood lead test, but a second 
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capillary can confirm it, a venous test is not required. While this factor is controlled for in 
Table 2, there was a large difference in the number of refugee children in Manchester 
receiving a capillary test compared to Providence. And lastly, over 60% of the nonrefugee 
children in Providence had their blood lead test between 1995 and 2002, compared with only 
13% nonrefugee children in Manchester. This was the time before CDC recommended 
primary prevention as a way to reduce EBLLs in children. After the switch from secondary 
to primary prevention, the country, as a whole, saw a temporal trend to lower numbers of 
EBLLs. Therefore, the number of children with EBLLs was much higher compared to the 
later years in the study. We were not able to remove these children from the analysis due to a 
reduction in power that would have made the analysis less precise.
For over 50 years, deteriorated lead-based paint from older homes has been the most 
frequent high-dose lead source for children with EBLLs (Pirkle et al., 1994). While age-
related risk is well documented in U.S. children (Brody et al., 1994), it does not predict risk 
for refugee children (Geltman et al., 2001).
As expected, we found that the length of time for refugee children’s BLLs to drop below 10 
μg/dL depended on the time of the blood lead test (i.e., before or after recommendations 
were established for refugee children). To our knowledge, no one has tested the effectiveness 
of these CDC recommendations regarding refugee children. In 2004, CDC’s Lead Poisoning 
Prevention The New Hampshire case study demonstrated that although some children had 
EBLLs when they arrived in the United States, the majority of the children did not, which 
proved to be important data on which to establish the need for a second blood lead test 
(Kellenberg et al., 2005).
Refugee children appeared to be followed more closely after recommendations were 
established and their EBLLs decreased significantly faster (mean time: 889 days to 471 
days, 47% reduction in time, p = .01). The time-to-decline to less than 10 μg/dL was 
appreciably shorter after the recommendations were in place. While there was an overall 
decrease in the mean days-to-decline for nonrefugee children before and after 
recommendations (793–507 days, 36% reduction in time, p = .05), the refugee children 
declined at an even faster rate (889–471 days).
An examination of the difference in mean days-to-decline among nonrefugee children before 
and after the recommendations became effective reflected other changes to screening, case 
management, and reporting laws. In the early 1990s, CDC recommended universal 
screening. In 1997, CDC released a new document that recommended targeted screening to 
high risk children. Over the course of the study years, NH and RI each lowered their levels 
for initiating case management and reporting laws from laboratories to send all blood lead 
test, not just elevated ones, also played a role. The refugee children with EBLLs are 
dropping to below 10 μg/dL faster now than before the recommendations’ effect. The public 
health importance of this recommendation and the effect it has had is important—not only in 
preventing EBLLs, but also in identifying those in need of care.
A limitation of this study was an inability to control for other important demographic risk 
factors. These factors, including for example race, may have influenced BLL time-to-decline 
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to fewer than 10 μg/dL. In addition, we did not have medical information on children with 
high BLLs or whether chelation therapy was administered, which may have influenced their 
time-to-decline. There were seven children in the survival analysis with EBLL’s over 45 
μg/dL who would have been eligible for chelation therapy. We did not have measures of iron 
status for most of the refugee children, which may have affected both their risk of 
developing an EBLL as well the time-to-decline to less than 10 μg/dL.
Our analysis was also limited by an inability to calculate the exact time-to-decline to fewer 
than 10 μg/dL. We did not know precisely when BLLs declined to less 10 μg/dL. We only 
knew when the children were tested and when their BLLs fell below 10 μg/dL and had to 
estimate time to the event. As a result, 37.6% of refugee and nonrefugee children were 
censored before their BLLs fell below 10 μg/dL, suggesting that many of the children with 
EBLLs may have been lost to follow-up. Also, we do not have information on how long 
these children were living in the addressing before their blood lead test. This could influence 
the EBLL as well as the time-to-decline.
Lastly, a potential study limitation could be a misclassification of refugee status before the 
CDC recommendations became effective. Both CLPPPs match their blood lead data with the 
Refugee Resettlement Agency on a regular basis, including linking older data. Looking at 
potential misclassified refugee children (coded as nonrefugee children), using last name as a 
proxy, showed an additional 12 confirmed EBLLs and 56 children with lower BLLs. The 
change in odds ratio showed a bias toward the null (OR = 1.08–.99). Given this potential 
misclassification, we believe the odds of refugee child having an EBLL may be less than 
what we have reported.
This study of 1,007 refugee children and 953 nonrefugee children living at the same 
addresses adds significant information to the body of literature examining the CDC 
recommendations for refugee children entering the United States and having timely blood 
lead tests and follow-up the CDC recommendations also incorporate early postarrival 
evaluation and therapy. These procedures include a nutritional evaluation for the child’s iron 
status to include a hemoglobin/hematocrit and one or more of the following: mean 
corpuscular volume combined with red cell distribution, ferritin, transferring saturation, or 
reticulocyte hemoglobin content. Other studies have found a connection between iron levels, 
race, and EBLLs regardless of refugee status (Raymond, Anderson, Feingold, Homa, & 
Brown, 2009).
Refugee children are eligible for Medicaid for at least 8 months after arrival in the United 
States. Blood lead testing complies with Medicaid’s Early and Periodic Screening, 
Diagnosis, and Treatment requirements for clinical care of young children. Our findings 
highlight the importance of this policy as well as CDC’s recommendations for testing and 
follow-up of refugee children. We therefore recommend:
• Continued blood lead testing as part of the medical screening of all newly arrived 
refugee children. In that way appropriate medical, educational, and 
environmental management may be initiated promptly.
• Continued evaluation of possible new nontraditional exposure sources to lead.
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• Continued timely follow-up testing of confirmed cases of EBLL.
Refugee children under 2 years of age are more at risk for having an elevated BLL than are 
nonrefugee children at least 6 years of age. Since the recommendations for testing refugee 
children for lead have been in place, time-to-decline has been reduced by more than 1 year. 
In addition, blood lead levels for refugee and nonrefugee children with elevated BLLs have 
declined at the same rate. The CDC recommendations appear to have helped establish 
guidelines for testing refugee children in a timely manner and to have helped establish 
guidelines for follow-up testing that have proved important (Caron et al., 2001). Testing of 
refugee children upon arrival into the United States should continue. Follow-up testing of 
those with confirmed EBLL is also strongly encouraged.
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Figure. 
Kaplan-Meier curves of the time required for blood lead levels to drop below 10 μg/dL 
before and after recommendations were established, stratified on refugee status, of children 
in Manchester, NH and Providence, RI
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8
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.6
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6
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.3
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5
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2
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5
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03
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0
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2
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5
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11
4
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16
3
36
.9
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9
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2
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.0
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9
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2
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9
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.6
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7
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)
0.
02
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0
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(0.
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2
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9
0.
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–1
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)
0.
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5
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8
1.
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8
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(0.
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0.
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3
-
-
-
-
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m
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f
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5
1.
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04
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5
1.
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 C
I
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